Does Glucosamine Actually Work for Dogs With Arthritis?Why a biologically plausible supplement has struggled to produce consistent clinical results.

By Steve Mehler, DVM, DACVS

The short answer: glucosamine is generally well tolerated, but the best available veterinary evidence does not show a reliable, clinically meaningful benefit for most dogs with osteoarthritis. It should not displace treatments with stronger evidence.

Few supplements have become as closely associated with canine arthritis as glucosamine. It appears in tablets, chews, powders, prescription diets, and combination products. Owners often begin it at the first sign of stiffness, and many continue it for years because it feels like a safe way to “support the joint.”

The idea is appealing. Glucosamine is involved in the production of glycosaminoglycans, which are components of cartilage and joint fluid. If osteoarthritis involves cartilage damage, supplying more of a cartilage building block seems logical. But a plausible mechanism is only the beginning of the evidence chain. The real question is whether an oral supplement reaches the joint in a useful form and amount—and whether dogs actually move better or hurt less because of it.

Why the theory is stronger than the clinical evidence

Osteoarthritis is not simply a matter of worn-out cartilage that can be replenished by adding raw ingredients. It is a whole-joint disease involving cartilage, synovium, subchondral bone, ligaments, muscles, inflammation, altered biomechanics, and chronic pain processing. Once that system is changing, providing a single nutrient does not automatically reverse it.

Oral delivery adds another hurdle. Canine pharmacokinetic work confirms that glucosamine can be absorbed, but exposure varies with formulation; liquid preparations may produce higher peak concentrations than chewable or tablet products. Even measurable absorption, however, does not prove that enough active material reaches arthritic cartilage to change pain or function. Pharmacokinetics can establish exposure. Clinical trials must establish benefit.

What clinical trials in dogs have found

The canine literature is mixed, but the most persuasive studies are not especially encouraging for glucosamine-chondroitin as a stand-alone arthritis treatment.

A 2003 randomized study found no objective benefit

Moreau and colleagues studied 71 client-owned dogs with osteoarthritis in a prospective, double-blind trial comparing a nutraceutical, carprofen, meloxicam, and placebo. Objective force-platform measurements improved with carprofen and meloxicam, but not with the nutraceutical. That distinction matters: force-plate analysis measures how much weight a dog places through the affected limb rather than relying only on impressions of improvement.

A 2007 trial reported improvement—but had important limits

McCarthy and colleagues compared a glucosamine-chondroitin combination with carprofen in 35 dogs that completed the study. Veterinarians reported improvements in pain, weight-bearing, and disease severity by day 70 in the supplement group. The onset was slower than with carprofen. However, the study did not include a placebo group, and the outcomes were based on subjective veterinary scoring. The result is worth acknowledging, but it is not definitive proof that glucosamine itself produced the change.

A 2023 placebo-controlled trial again failed to show a glucosamine effect

A more recent randomized, double-blinded, placebo-controlled study assigned 75 dogs with hip osteoarthritis to glucosamine-chondroitin, two marine fatty-acid products, carprofen, or placebo. Peak vertical force improved with carprofen and the marine fatty-acid interventions at specified time points, while the glucosamine group did not separate meaningfully from placebo. This study is especially useful because it compared several commonly used options with both an active control and a true placebo.

What the systematic review concluded

The clearest overview comes from a 2022 systematic review and meta-analysis of enriched diets and nutraceuticals for canine and feline osteoarthritis. The authors found a “very marked non-effect” for chondroitin-glucosamine products. In contrast, marine omega-3 interventions had substantially stronger support.

Important distinction: a positive study of a multi-ingredient joint supplement does not prove that glucosamine was the effective ingredient. Chondroitin, green-lipped mussel, omega-3 fatty acids, collagen, Boswellia, or other compounds may be present at the same time.

Why owners may still believe it works

This does not mean owners are dishonest or imagining their dog’s improvement. Osteoarthritis naturally fluctuates. Dogs have better days and worse days. Activity, weather, rest, concurrent medication, weight change, and household routine can all influence mobility. Owners also tend to start a supplement when signs are particularly bad; some improvement may occur as the flare settles, even without an effective treatment.

Expectation adds another layer. In a 2012 study of dogs receiving placebo for osteoarthritis-associated lameness, owners perceived improvement about 40% of the time. Veterinarians also recorded apparent improvement in roughly 43% to 45% of assessments, even though average objective ground-reaction forces did not change. This is the caregiver placebo effect: a genuine change in human perception, not necessarily a biological treatment effect in the dog.

Is glucosamine dangerous?

For most dogs, glucosamine-chondroitin products appear to be relatively well tolerated. That is one reason they remain popular. But “probably safe” and “proven effective” are different standards. A low-risk product can still carry opportunity costs: money spent for little benefit, extra calories from chews, gastrointestinal upset, product-quality variability, and—most importantly—delay of treatments that more reliably control pain.

Supplements also vary in salt form, concentration, additional ingredients, manufacturing quality, and actual content. A study of one branded combination cannot automatically validate every product on the shelf.

What should owners do instead?

Canine osteoarthritis is best managed as a multimodal disease. The plan should be individualized, but the most useful discussion usually includes:

Weight optimization when appropriate, because excess load amplifies joint stress.

Regular, controlled exercise that preserves muscle without repeatedly provoking a flare.

Veterinary-directed analgesic and anti-inflammatory medication when indicated.

Rehabilitation, home modification, traction, ramps, and activity adjustments.

Marine omega-3 fatty acids or an omega-3-enriched therapeutic diet when appropriate.

Monitoring with repeatable measures—such as walking tolerance, stair use, validated pain inventories, or objective gait data—rather than relying on memory alone.

If a dog is already taking glucosamine, there is usually no reason to panic or stop abruptly. Instead, ask a practical question: can we identify a meaningful improvement? A structured trial with predefined goals is more informative than continuing indefinitely because the product “might be helping.” If no reproducible change is visible, the supplement may not be earning its place in the treatment plan.

The bottom line

Glucosamine remains popular because the theory is intuitive, the products are accessible, and the downside often appears small. But decades of use do not substitute for strong clinical evidence. Across controlled trials and systematic review, glucosamine-chondroitin has not demonstrated a consistent, clinically meaningful benefit for dogs with naturally occurring osteoarthritis.

That does not mean every dog receiving a combination supplement will fail to improve. It means we should be careful about attributing that improvement to glucosamine—and we should not allow an uncertain supplement to replace weight management, appropriate exercise, rehabilitation, effective analgesia, and other treatments with stronger support.

My practical takeaway: glucosamine is unlikely to be harmful for most dogs, but it is also unlikely to be the treatment that meaningfully changes their arthritis. Measure outcomes, prioritize proven therapies, and make every component of the plan justify its place.

References

Barbeau-Grégoire M, Otis C, Cournoyer A, et al. A 2022 systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis. Int J Mol Sci. 2022;23(18):10384. doi:10.3390/ijms231810384

Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 2003;152(11):323-329. doi:10.1136/vr.152.11.323

McCarthy G, O’Donovan J, Jones B, et al. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. 2007;174(1):54-61. doi:10.1016/j.tvjl.2006.02.015

Kampa N, Kaenkangploo D, Jitpean S, et al. Study of the effectiveness of glucosamine and chondroitin sulfate, marine-based fatty acid compounds, and carprofen for dogs with hip osteoarthritis. Front Vet Sci. 2023;10:1033188. doi:10.3389/fvets.2023.1033188

Maxwell LK, Regier P, Achanta S. Comparison of glucosamine absorption after administration of oral liquid, chewable, and tablet formulations to dogs. J Am Anim Hosp Assoc. 2016;52(2):90-94. doi:10.5326/JAAHA-MS-6267

Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. J Am Vet Med Assoc. 2012;241(10):1314-1319. doi:10.2460/javma.241.10.1314